OBJECTIVE: To determine the role of newer fluoroquinolones (FQs) for adults with
community-acquired pneumonia (CAP) whose level of illness allows treatment with an oral …

Background: We investigated whether the use of respiratory fluoroquinolones was
associated with better clinical outcomes compared with the use of macrolides and β-lactams …

Community-acquired pneumonia (CAP) is a leading cause of morbidity and mortality. This
review compared two of the main treatment alternatives: quinolone or macrolide …

Community‐acquired pneumonia (CAP) remains a major cause of morbidity and mortality
worldwide. The treatment of CAP has been complicated by several factors, including the …

Aims: Review of the current guidelines for the use of respiratory fluoroquinolones in the
management of community‐acquired pneumonia (CAP). Methods: Data were collected from …

Introduction Guidelines recommend respiratory fluoroquinolone monotherapy or β-lactam
plus macrolide combination therapy as first-line options for hospitalized adults with mild to …

Background: The choice of empirical antibiotic treatment for patients with community-
acquired pneumonia (CAP) who are admitted to non-intensive care unit (ICU) hospital wards …

Background Increasing use of broad-spectrum antibiotics in the community, including
fluoroquinolones, has been reported, despite concerns for developing antibiotic resistant …

Guidelines for inpatients with community-acquired pneumonia (CAP) propose to use
respiratory fluoroquinolone (RFQ) and/or third-generation cephalosporins (Ceph-3) …

Fluoroquinolone use has dramatically increased since the introduction of the first respiratory
fluoroquinolone in the late 1990s. Over a relatively brief period of time, the respiratory …